IMPROVED SURVIVAL IN ANAL CANAL CANCER WITH COMBINED CHEMOTHERAPY RADIOTHERAPY (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

IMPROVED SURVIVAL IN ANAL CANAL CANCER WITH COMBINED CHEMOTHERAPY RADIOTHERAPY (MEETING ABSTRACT)

Clin Res; 39(3):668A 1991. Unique Identifier : AIDSLINE ICDB/92679840
Grossi CE; Soltani J; Narasimhan P; Gonzalez R; Glasberg S; Friedman D; Dept. of Surgery, LaGuardia Hosp., H.I.P., Forest Hills, NY 11375

Abstract: The aim was to see if multidisciplinary care changed outcome in anal canal cancer. Treatment modalities and results of anal canal cancer were compared between the periods 1976-1980 and 1981-1990. In these periods there was a total of 23 patients (pts) seen, 7 of them in 1976-1980 and 16 in 1981-1990. HIV infected pts were excluded. There has been a recent increase in HIV-infected pts with anal canal cancers and lymphomas and these carry a poorer prognosis. Perianal and anal canal warts were often associated with this malignancy. Pts with these conditions should be monitored carefully for malignant changes. For the first group of pts there were 5 females, and 2 males who had abdominoperineal resection with colostomy, with 1 survivor. In the second group, 8 out of 16 pts were female. In the second decade, combined chemotherapy (5FU and mitomycin C) was given for 5 days at onset of 5 wk of radiation therapy. Biopsy was performed 1 mo after completion of radiotherapy. If positive, radical surgery and colostomy were done. If biopsy was negative, one more course of 5-day chemotherapy was given and surgery was avoided. In the 1- to 10-yr follow-up, there were 10 survivors free of cancer in the 16 pts (60%). This combined chemotherapy and radiotherapy protocol has changed the management of this rare malignancy.

Keywords: Anus Neoplasms/DRUG THERAPY/PATHOLOGY/RADIOTHERAPY/*THERAPY Combined Modality Therapy Female Fluorouracil/THERAPEUTIC USE Human Male Mitomycin C/THERAPEUTIC USE Warts/COMPLICATIONS ABSTRACT
920430
M9240935

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .